Drug Type CAR-T |
Synonyms FCTX-CL-19-1 |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-Cell Malignant Neoplasm | Phase 1 | Poland | 24 May 2023 | |
| Diffuse Large B-Cell Lymphoma | Phase 1 | Poland | 24 May 2023 | |
| Large B-cell lymphoma | Phase 1 | Poland | 24 May 2023 | |
| Mantle-Cell Lymphoma | Phase 1 | Poland | 24 May 2023 | |
| Refractory B Acute Lymphoblastic Leukemia | Phase 1 | Poland | 24 May 2023 |





